Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 7/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 7/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MLYCD | O95822 | 4/20 | 0.37 |
| ▸ | FPR2 | P25090 | 3/20 | 0.35 |
| ▸ | FPR3 | P25089 | 2/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL983152 | 0.80 | GPR119 (0.48) | NPSR1HSD17B10MAPT | |
| SCHEMBL20789296 | 0.80 | GPR119 (0.42) | — | |
| SCHEMBL21381142 | 0.79 | HRH3 (0.38) | UBE2MDCUN1D1LMNATP53POLB | |
| SCHEMBL19975384 | 0.78 | MLYCD (0.38) | UBE2MDCUN1D1LMNATP53POLB | |
| SCHEMBL12810893 | 0.78 | CCR5 (0.36) | LMNATP53POLBMLYCDCHRM4 | |
| SCHEMBL17203791 | 0.78 | — | — | |
| SCHEMBL12539166 | 0.78 | TDP1 (0.35) | MLYCDGAA | |
| SCHEMBL20789238 | 0.77 | FPR3 (0.38) | MLYCDFPR2FPR3 | |
| SCHEMBL20789235 | 0.77 | FPR3 (0.38) | MLYCDFPR2FPR3 | |
| SCHEMBL28781197 | 0.75 | MLYCD (0.33) | UBE2MDCUN1D1LMNATP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681884-A1 | RAD51 INHIBITORS | Cyteir Therapeutics, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019051465-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| US-8481524-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2205589-B1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2205589-A2 | C-MET PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009045992-A2 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-09 | — | — | WO | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | UBE2M 3975/4885DCUN1D1 1728/4885LMNA 3592/4885 |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | UBE2M 3364/4885DCUN1D1 1816/4885LMNA 3472/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | UBE2M 3364/4885DCUN1D1 1816/4885LMNA 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.